Nanobiotix (NASDAQ:NBTX; Euronext:NANO) has announced the dosing of the first patient in its CONVERGE Phase 2 study, evaluating its potential first-in-class radioenhancer, JNJ-1900 (NBTXR3), in patients with stage 3 non-small cell lung cancer (NSCLC).
The company noted that the CONVERGE study is sponsored by Janssen, a Johnson & Johnson company, under a global licencing agreement. The study is a Phase 2 randomized controlled clinical trial.
“We believe the true value of JNJ-1900 (NBTXR3) is driven by its potential to address the unmet needs of the millions of patients each year who receive radiotherapy as part of their treatment,” Laurent Levy, CEO and chairman of Nanobiotix stated.
“With a clear path to potential registration in head and neck cancer established through NANORAY-312, the first patient dosed in the CONVERGE study in NSCLC brings us another step closer to delivering for the large number of patients JNJ-1900 (NBTXR3) is designed to serve,” Mr. Levy concluded.
